Cambridge Isotope Laboratories, Inc. Reveals Details on Headquarters Relocation and Expansion Plans

Cambridge Isotope Laboratories, Inc. (CIL), a leader in stable isotope chemistry, has announced plans to relocate and expand its corporate headquarters. The new location, a two-building campus in Tewksbury, MA, spans 150,000 square feet on 25 lakefront acres. This move aims to foster product development and future growth, according to a statement made on March 15, 2024. The expansion includes a new 8,000-square-foot research and development (R&D) facility and larger cGMP, QC, formulations, and production labs.

Chief Science Officer Todd Osiek highlighted the high demand for stable isotope-labeled compounds and the opportunities the new R&D facility will bring for developing new products and investing in advanced technologies. The expansion allows CIL to produce commercial-grade Active Pharmaceutical Ingredients (APIs) labeled with stable isotopes on a larger scale, improving capacities for clinical trial materials. CEO Cliff Caldwell emphasized that the new development not only benefits employees with a dynamic work environment but also significantly enhances research, development, and production capacities.

CIL will maintain operations at its current headquarters and Andover production facility during the transition to the new Ames Pond campus. The Andover location will remain operational post-move. This strategic expansion reflects CIL's commitment to advancing its capabilities in stable isotope chemistry, supporting its mission to innovate and serve its global customer base more effectively.